EPIDEMIOLOGY AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC RENAL FAILIRE AND ANEMIA, RECEIVING PROGRAMM HEMODYALISISPart 1. Epidemiology and use of erythropoietin medications
- Authors: Vorob'ev PA1, Bezmel'nitsyna LY.1
-
Affiliations:
- Issue: No 1 (2011)
- Pages: 46-51
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245956
- ID: 245956
Cite item
Full Text
Abstract
Aim. Study of epidemiology and quality of life in patients with terminal renal failure and anemia, receiving program hemodyalisis.
Methods. Results of survey of 1395 patients with terminal renal failure and anemia, receiving program hemodyalisis, were analyzed.
Results. Mean age of patients were 42 years, 20% - >60 years. Main etiological causes of terminal renal failure were chronic glomerulonephritis and chronic pyelonephritis. 84% of patients had chronic kidney disease >2 years, 21,5% - >20 years. Majority of patients had concomitant diseases, 44,5% - visual disturbances. 72,7% had hemoglobin level > 100 g/l, 48,7% - >110 g/l; 26,8 - <100 g/l, 5,3% - < 80 g/l. 5% of patients during previous month received haemotransfusions. 83,5% received erythropoietin medications, predominantly Recormon and Eralfon. In 17 patients Eralfon was displaced by other erythropoietin medications; in 174 other erythropoietin medications were displaced by Eralfon .
Conclusion. Epidemiological characteristics of patients with terminal renal failure and anemia, receiving program hemodyalisis should lead to improvement of their management in routine clinical practice.
Methods. Results of survey of 1395 patients with terminal renal failure and anemia, receiving program hemodyalisis, were analyzed.
Results. Mean age of patients were 42 years, 20% - >60 years. Main etiological causes of terminal renal failure were chronic glomerulonephritis and chronic pyelonephritis. 84% of patients had chronic kidney disease >2 years, 21,5% - >20 years. Majority of patients had concomitant diseases, 44,5% - visual disturbances. 72,7% had hemoglobin level > 100 g/l, 48,7% - >110 g/l; 26,8 - <100 g/l, 5,3% - < 80 g/l. 5% of patients during previous month received haemotransfusions. 83,5% received erythropoietin medications, predominantly Recormon and Eralfon. In 17 patients Eralfon was displaced by other erythropoietin medications; in 174 other erythropoietin medications were displaced by Eralfon .
Conclusion. Epidemiological characteristics of patients with terminal renal failure and anemia, receiving program hemodyalisis should lead to improvement of their management in routine clinical practice.
References
- Бикбов Б.Т., Томилина Н.А. О состоянии заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2003 гг. (отчет по данным регистра Российского диализного общества) Нефрология и диализ. 2005; 7(3): 204-276
- Hsu C.Y., McCulloch C.E., Curhan G.C. Epydemiology of anemia associated with chronic renal insufficiency among adult in the United States. J Am Soc Nephrol. 2002; 13: 504-510
- Воробьев П.А. Недостаточность функций почек (патогенез, диагностика, терапия). М.: Ньюдиамед-АО, 1998., 64 с.
- Astor B.C., Muntner P., Levin A. Et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162: 1401-1408
- Levin A., Thompson C.R., Ethier J. et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999; 34: 125-134.
- Rossert J, Levin A., Roger S.D. et al. Effect of early correction of anemia on the progression of chronic kidney disease. Am J Kidney Dis. 2006; 5: 738-750
- Drueke T., Locatelly F., Cline N. CREATE (Cardiovascular risk Reduction by Early Anemia Treatment with Erythropoetin. N Engl J Med; 2006; 355: 2071-2084.
- Singh A., Szczech L., Tang K. et al. CHOIR (Correction of anemia with epoetin alfa in chronic kidney disease) N Engl J Med. 2006; 355: 2085-2098.
- National Kidney Foundation: K/DOQI clinical practice guidelines for аnemia of chronic kidney disease, 2000. Am J Kidney Dis; 2001; 37(suppl 1): S182-S238.
- National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002; 39 (suppl 1): 1 - 127.
- Health care cost, quality, and outcomes. ISPOR book of terms. ISPOR: Lawrenceville, NJ, 2003., 264 p.
Supplementary files
